Timely treatment with direct-acting antivirals is highly cost-effective in virtually all patients infected with HCV.
An innovative telemedicine model could substantially reduce the burden of chronic hepatitis C infection.
The benefits of HCV treatment will need to extend to all patients in order to stem the rising tide of HCV complications among women and men.
Week 4 HCV RNA levels have implications for treatment with direct-acting antiviral agents for hepatitis C virus infections.
Direct-acting antiviral therapy with sofosbuvir-based combinations safely and effectively treats HCV infection in patients with early-stage chronic kidney disease.
A new study suggests a public health approach is necessary to control the spread of hepatitis C virus in urban communities.
Liver transplant outcomes have improved following the introduction of new hepatitis C virus drugs, according to a new study.
Primary care professionals can “substantially expand” HCV treatment in the community, according to new research.
A new report highlights key missing elements needed to achieve complete elimination of hepatitis C virus.
A sustained response to direct-acting antivirals lowers the risk of hepatocellular carcinoma, a new study finds.